参考文献/References:
[1] 梁 衍,闫晓辉.高位结肠透析联合肾康栓保留灌肠治疗慢性肾脏病的疗效观察[J].临床医学研究与实践,2016,15(1):18-19.
[2] Dersky AS,Mclaugh JR,Baker JP,et al.What is subjective global assessment of nutritional status[J].Parenter Enterol Nutr,1987,11(1):8-13.
[3] 中国行为医学科学编辑委员会.行为医学量表手册[M].北京:中华医学电子音像出版社,2005:223-224.
[4] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:163-168.
[5] Louis E,Tack J,Vandenhoven G,et al.Evaluation of the GERD impact scale an international validated patient questionnaire in daily practice results of the alegria study[J].Acta Gastroenterol Belg,2009,72(1):3-8.
[6] Urganci N,Ozcelik G,Kalyoncu D,et al.Serum gastrin levels and gastroduodenal lesions in children with chronic renal failure on continuous ambulatory peritoneal dialysis:A single-center experience[J].Eur J Gastroenterol Hepatol,2012,24(10):924-928.
[7] Bacci M,Russo F,Carvalho G,et al.Endoscopic alterations in acohort of hemodialysis patients:A cross-sectional study[J].Int J Gen Med,2014,16(7):459-461.
[8] Borazan A,Cavdar Z,Saglam F.The effect of renal replacementtherapies on serum gastrointestinal system hormones[J].Ren Fail,2007,29(8): 1019-1023.
[9] 张 静,郭立华,姜 琦,等.胃肠肽激素在慢性肾功能衰竭患者行血液透析后的变化影响[J].现代消化及介入诊疗,2016,21(1):135-137.
[10] Dejardin A,Robert A,Goffin E.Intraperitoneal pressure in PD patients:Relationship tointraperitoneal volume body size and PD-related complications[J].Nephrol Dial Transplant,2007,22(5): 1437-1444.
[11] Van V,Schoonjans RS,Struijk DG,et al.Influence of dialysate on gastric emptying time in peritoneal dialysis patients[J].Perit Dial Int,2002,22(1): 32-38.
[12] Santos PR,Monteiro DL,De PH,et al.Volaemic status and dyspepsia in end-stage renal disease patients[J].Nephrology(Carlton),2015,20(8):519-522.
[13] Salles LD,Santos PR,Santos AA,et al.Dyspepsiaand gastric emptying in end-stage renal disease patients on hemodi-alysis[J].BMC Nephrol,2013,14(14):275-279.
[14] 魏金花,张翠芹.辨证分型应用中药结肠透析治疗慢性肾衰竭早中期32例疗效观察[J].中国中西医结合肾病杂志,2014,15(3):228.
[15] 段昱芳,张海滨.结肠透析治疗慢性肾脏病2-4期65例患者的疗效观察[J].中国中西医结合肾病杂志,2015,16(5): 444-445.
[16] 高辰馨,张勉之.补肾活血法配合结肠透析治疗早中期慢性肾衰竭的短期临床观察[J].中华中医药杂志,2014,29(6):2063-2065.
[17] 海广范,詹合琴,许 华,等. nmhaFGF对肾脏缺血再灌注损伤大鼠不同时间SOD、MDA、BUN、Cr和尿蛋白含量的影响[J].陕西医学杂志,2009,38(7):774-777.
[18] 马 丽,何 帆,杨文君. 联机和高通量血液透析单独与贯序应用对于终末期肾病患者透析充分性和生活质量的影响[J].重庆医学,2019,48(8):1354-1358,1362.
[19] 李柱宏,李开龙,杨聚荣,等. 血液透析联合血液滤过清除尿毒症患者血清成纤维细胞生长因子23的效果观察[J].中华临床医师杂志:电子版,2012,6(4):897-900.
[20] 林 钐.不同方式中药结肠透析在慢性肾脏病的研究进展[J].中国中西医结合肾病杂志,2019,20(1):80-81.
[21] 周 刊,吕冬宁,曾海飞.中药结肠透析治疗慢性肾衰竭临床应用进展[J].广西中医药大学学报,2019,22(2):63-65.
[22] 杨淑彬,陈婉丽.中药结肠透析改良法治疗慢性肾衰竭疗效观察[J].陕西中医,2015,36(12):1616-1617.
[23] 段连香,刘子洋,陈 杰,等. 叶氏降酐合剂结肠透析治疗湿热蕴结型慢性肾脏病4期患者的短期疗效观察[J].中国中西医结合肾病杂志,2022,23(5):435-437.
[24] 毛东东,熊 飞,周文祥,等. 参芪肾衰合剂联合结肠透析对慢性肾脏病4期(脾肾气虚证)患者的临床疗效观察[J].临床肾脏病杂志,2022,22(6):465-470.
[25] 晏慧民,童 薇,邱国萍. 中药结肠透析联合尿毒清颗粒对慢性肾脏病3-5期患者疗效及肾功能指标的影响[J].中国当代医药,2022,29(19):105-108.
相似文献/References:
[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(12):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(12):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(12):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(12):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(12):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(12):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(12):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[9]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(12):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
[10]王禹霖,刘梦超,郑冰洁,等.名中医张炳厚从瘀论治慢性肾脏病经验撷英[J].陕西中医,2023,(11):1602.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.026]
WANG Yulin,LIU Mengchao,ZHENG Bingjie,et al.Experience of famous Chinese doctor Zhang Binghou treating chronic kidney disease by Yu[J].,2023,(12):1602.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.026]